Vimarsana
Biggest News Aggregation in the World

Page 2 - With Determination News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from With Determination. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In With Determination Today - Breaking & Trending Today

Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio - Vimarsana News

Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio

Published: November 3, 2022

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today...

Source: prnewswire.com
Related Topics:
United StatesHemophagocytic LymphohistiocytosisObrian KenneyTyrone BrewerPeter LebowitzCaroline PavisJanssen Biotech IncEuropean Hematology AssociationMomenta Pharmaceuticals IncJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonAmerican Society Of HematologyUniversity Of MunichNone Of The Janssen Pharmaceutical CompaniesOther Administration ReactionsDrug AdministrationEuropean CommissionExchange CommissionCompanies Of JohnsonInternational Myeloma Society Annual MeetingLegend Biotech United States IncAmerican SocietyAnnual MeetingNew Orleans
Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Vimarsana News

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Published: August 28, 2022

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study...

Source: prnewswire.com
Related Topics:
United StatesBortezomib MelphalanDouglasw SborovVelcade MelphalanVelcade Bortezomib MelphalanImran KhanChristie CorbettMyeloma ProgramJanssen Biotech IncUniversity Of UtahJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonNational Library Of MedicineEuropean Myeloma NetworkAmerican Cancer SocietyNone Of The Janssen Pharmaceutical CompaniesHematology At Janssen Scientific AffairsHuntsman Cancer InstituteInternational Myeloma SocietyExchange CommissionCompanies Of JohnsonInternational Myeloma Society Annual MeetingMultiple Myeloma ProgramMedical Affairs
Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Press Release - Vimarsana News

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Press Release

Published: August 27, 2022

Data featured in plenary session at the 19th International Myeloma Society Annual Meeting LOS ANGELES, Aug. 27, 2022 /PRNewswire/ -- The Janssen Pharm

Source: wiredprnews.com
Related Topics:
United StatesBortezomib MelphalanDouglasw SborovVelcade MelphalanVelcade Bortezomib MelphalanImran KhanChristie CorbettMyeloma ProgramJanssen Biotech IncUniversity Of UtahJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonNational Library Of MedicineEuropean Myeloma NetworkAmerican Cancer SocietyNone Of The Janssen Pharmaceutical CompaniesHematology At Janssen Scientific AffairsHuntsman Cancer InstituteInternational Myeloma SocietyExchange CommissionCompanies Of JohnsonInternational Myeloma Society Annual MeetingMultiple Myeloma ProgramMedical Affairs
Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Vimarsana News

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Published: August 27, 2022

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study...

Source: prnewswire.com
Related Topics:
United StatesBortezomib MelphalanDouglasw SborovVelcade MelphalanVelcade Bortezomib MelphalanImran KhanChristie CorbettMyeloma ProgramJanssen Biotech IncUniversity Of UtahJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonNational Library Of MedicineEuropean Myeloma NetworkAmerican Cancer SocietyNone Of The Janssen Pharmaceutical CompaniesHematology At Janssen Scientific AffairsHuntsman Cancer InstituteInternational Myeloma SocietyExchange CommissionCompanies Of JohnsonInternational Myeloma Society Annual MeetingMultiple Myeloma ProgramMedical Affairs
Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Vimarsana News

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Published: August 27, 2022

Data featured in plenary session at the 19th International Myeloma Society Annual Meeting LOS ANGELES, Aug. 27, 2022 /PRNewswire/ -- The Janssen P...

Source: businessinsider.com
Related Topics:
United StatesBortezomib MelphalanDouglasw SborovVelcade MelphalanVelcade Bortezomib MelphalanImran KhanChristie CorbettMyeloma ProgramJanssen Biotech IncUniversity Of UtahJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonNational Library Of MedicineEuropean Myeloma NetworkAmerican Cancer SocietyNone Of The Janssen Pharmaceutical CompaniesHematology At Janssen Scientific AffairsHuntsman Cancer InstituteInternational Myeloma SocietyExchange CommissionCompanies Of JohnsonInternational Myeloma Society Annual MeetingMultiple Myeloma ProgramMedical Affairs